October 27, 2026

Seattle Sperm Bank

MEDICAL UPDATE LETTER FOR DONOR #14232 (SHUFEN) - 2026-10-27

Donor 14232 (Shufen) was recently reported to be a carrier of a genetic condition, oculocutaneous albinism type II. This condition was not included on his prior carrier screening panel. This letter is intended for all recipients and facilities who have utilized vials from Donor 14232 (Shufen) to make them aware and provide follow-up suggestions.

To Whom it May Concern,

We are writing to provide a medical update regarding Donor #14232 (Shufen).

Donor 14232 (Shufen) was determined to be a carrier of a clinically significant variant in the OCA2 gene. He is heterozygous (one copy) for a likely pathogenic variant in OCA2, specifically a deletion of exons 18-21.

The OCA2 gene is associated with autosomal recessive oculocutaneous albinism type II. Oculocutaneous albinism type II is characterized by reduced pigmentation in the skin, eyes, and hair. In affected individuals this can lead to vision problems and an increased risk of skin damage and cancer. Affected individuals inherit two mutations in the OCA2 gene, one from the egg source and one from the sperm source. Carriers of OCA2, like Donor 14232 (Shufen), are not expected to exhibit symptoms.

Interpretation:
All children/embryos resulting from Donor 14232 (Shufen) have a 50% chance to have inherited the OCA2 variant. Children/embryos who inherit one copy of the mutation would be asymptomatic carriers, just like the donor.

Next Steps for Families who have Utilized the Donor:

Please share this letter and the attached report with your doctors. The egg source of any embryos/children resulting from Donor 14232 (Shufen) may consider carrier screening for mutations in the OCA2 gene.

- If the egg source of any child/embryo is also a carrier of a mutation in the OCA2 gene, there is a 1 in 4 (25%) chance that each resulting child/embryo will inherit *both* mutations and be affected with oculocutaneous albinism type II.
- If the egg source of any child/embryo screens negative for mutations in the OCA2 gene, the risk to have a child affected with oculocutaneous albinism type II is significantly reduced.

Do not hesitate to reach out if questions arise or if clarification would be helpful. You are welcome to schedule a phone consultation with one of Seattle Sperm Bank's certified genetic counselors if you would like to discuss this information over the phone.

In partnership,

Emily Nazar, MS, CGC
Certified Genetic Counselor
Seattle Sperm Bank

Olivia Hess, MS, CGC
Certified Genetic Counselor
Seattle Sperm Bank

James Kuan, MD
Medical Director
Seattle Sperm Bank

(206) 588-1484
Genetics@SeattleSpermBank.com

(206) 588-1484
Genetics@SeattleSpermBank.com

(206) 588-1484
James@seattlespermbank.com

Seattle Sperm Bank (SSB) genetic counselors provide genetic information and education related to donor screening, family history, and medical updates. They are not the personal healthcare providers of SSB customers, donors, or their family members, and their communications do not establish a healthcare provider–patient relationship or replace formal clinical genetic counseling. Customers and donors should review this information with their own qualified healthcare providers to determine its relevance and whether additional evaluation, testing, or medical management is appropriate.